echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Ann Rheum Dis: Efficacy and safety of tanalizumab in the treatment of hip or knee osteoarthritis

    Ann Rheum Dis: Efficacy and safety of tanalizumab in the treatment of hip or knee osteoarthritis

    • Last Update: 2021-04-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Tanalizumab is a nerve growth factor inhibitor.


    From March 2016 to December 2017, the study recruited 849 patients with moderate to severe OA in Europe and Japan who did not respond or could not tolerate standard care analgesics.


     

    282 patients received placebo, 283 patients received 2.


    feeling abnormal

    In summary, the results of the study show that tanalizumab 5 mg can significantly improve the pain, body function and PGA-OA of patients with osteoarthritis, but tanalizumab 2.


     

    Original source:

     

    Francis Berenbaum, et al.


    ncbi.
    nlm.
    nih.
    gov/32234715/" target="_blank" rel="noopener">Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.